Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Lipella Pharmaceuticals Inc (LIPO)

Lipella Pharmaceuticals Inc (LIPO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
PR images (don't use) - Lipella_Pharma_v3_Logo
Lipella Pharmaceuticals Advances With Multiple Near-Term Catalysts and Strategic Focus on Rare Diseases Barchart Impact - Tue May 7, 8:01AM CDT

Lipella Pharmaceuticals is a clinical-stage biotechnology company that focuses on developing and commercializing treatments for serious diseases with significant unmet needs.

LIPO : 0.4454 (-2.56%)
Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing FinancialNewsMedia - Mon Oct 23, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:LIPO) EQNX::TICKER_END

ONCY : 1.0200 (-0.97%)
ONC.TO : 1.42 (+0.71%)
CRDF : 2.35 (+4.44%)
LLY : 865.97 (+0.99%)
ABBV : 173.61 (+0.75%)
LIPO : 0.4454 (-2.56%)
Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite PR Newswire - Mon Apr 17, 2023

/PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company addressing serious diseases...

LIPO : 0.4454 (-2.56%)
Lipella Pharmaceuticals Doses First Patient in Human Study of Innovative Contrast Agent PR Newswire - Wed Apr 5, 2023

/PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company addressing serious diseases...

LIPO : 0.4454 (-2.56%)
Lipella Provides Business Update and Reports 2022 Financial Results PR Newswire - Fri Mar 31, 2023

Company Successfully Completes Phase 2a Clinical Trial Fourth Quarter or Full Year Highlights • Appointed Douglas Johnston as CFO in November 2022 •...

LIPO : 0.4454 (-2.56%)

Barchart Exclusives

1 Reliable Dividend Stock to Buy at a Discount This July Barchart - Mon Jul 22, 6:30PM CDT
Here’s a dividend-paying gem trading at an attractive valuation, which investors can consider this July while it's still a bargain. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot